ResMed Inc. (RMD)
Healthcare · NYSE · US
Price as at 1 Oct 2026, 21:04 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
ResMed Inc. trades at $221.15, close to the $251.72 our fair value estimate puts on the business. On this measure the market and the model broadly agree, so the interesting question is which of them is wrong.
Our moat model scores it 88 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 19.6 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
RMD dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $1.86 | 3 |
| 2025 | $2.26 | 4 |
| 2024 | $2.02 | 4 |
| 2023 | $1.84 | 4 |
| 2022 | $1.72 | 4 |
| 2021 | $1.62 | 4 |
| 2020 | $1.56 | 4 |
| 2019 | $1.52 | 4 |
| 2018 | $1.44 | 4 |
| 2017 | $1.36 | 4 |
| 2016 | $1.26 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
RMD earnings and analyst estimates
Recommendation mix, 18 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About ResMed Inc.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
RMD passes 6 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
13 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$220.16M · 0.1% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$177.14M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$99.05M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$80.10M · 0.1% of book
- Francois Rochon, Giverny Capital Inc.$75.55M · 2.5% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in RMD
We hold 13 disclosed trades in RMD by members of Congress and executive-branch officials. The latest 5:
- Donald J Trump · Executive branchBuy · $1,001 - $15,000 · traded 23 Jun 2026 · disclosed 22 Aug 2026
- Donald J Trump · Executive branchBuy · $1,001 - $15,000 · traded 3 Jun 2026 · disclosed 22 Aug 2026
- Donald J Trump · Executive branchBuy · $50,001 - $100,000 · traded 22 May 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 18 May 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 11 May 2026 · disclosed 1 Jul 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
RMD peers
The largest companies in the same industry, then in the same sector.
- NOVO-B.CO Novo Nordisk
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- UNH UnitedHealth Group Incorporated
- NVSEF Novartis AG
- AZN AstraZeneca (ADR)
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is ResMed Inc. (RMD) undervalued?
Against our fair value estimate of $251.72, RMD at $221.15 is 14% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own RMD?
13 of the institutions we track reported a position in RMD in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is RMD's P/E ratio?
RMD trades at 19.6 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does ResMed Inc. (RMD) pay a dividend?
Yes. ResMed Inc. yields 1.15% at the current share price. It has paid $2.46 per share over the trailing twelve months. It has paid a dividend in each of the last 14 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its RMD data?
Fundamentals for RMD come from company filings and exchange data, as listed on NYSE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 21:04 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for RMD, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.